InnotiveDx (formerly PhenUtest), which is developing a novel point-of-care test to revolutionise the diagnosis and treatment of urinary tract infections (UTIs), has appointed Will Wijnberg as Chief Executive Officer. Formerly the company’s Chief Operating Officer, he has played a key role in the company’s progress since it was founded in 2021. His medtech experience includes taking a medical device to US FDA clearance earlier this year.

Will Wijnberg, CEO of InnotiveDx, said, ‘The ability of point-of-care diagnostics to play a significant role in more effective and efficient healthcare delivery, particularly in common infections such as UTIs, is a very exciting prospect. I’m delighted to have been appointed CEO at a significant time for the company, with device prototyping work progressing as we develop our clinical and regulatory path. As concern over the impact of antimicrobial resistance grows, rapid bacterial identification and antibiotic susceptibility tests such as ours have an important role to play by driving right-first-time treatment.’